In a clinical study of patients with MLL /KMT2A rearrangement, it was found that solid tumor therapy‐related AML (t‐AML), MLL t‐AML, had bad prognosis in comparison to non‐MLL t‐AML and MLL de novo AML, but allogeneic hematopoietic stem cell transplantation (allo‐HSCT) overcame the poor prognosis of MLL t‐AML [74]. Here, KMT2A is linked to acute myeloid leukemia.